An adjusted indirect treatment comparison (ITC) of enzalutamide (ENZ) versus docetaxel (DOC) for metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Ohlmann, Carsten [1 ]
Armstrong, Andrew [2 ]
Gratzke, Christian [3 ]
Sugg, Jennifer [4 ]
Ganguli, Arijit [4 ]
Dornstauder, Eugen [5 ]
Gross-Langenhoff, Marco [5 ]
Brauner, Reinhard [5 ]
Stenzl, Arnulf [6 ]
机构：
[1] Johanniter Krankenhaus Bonn, Bonn, Germany
[2] Duke Univ, Durham, NC USA
[3] Univ Klinikum Freiburg, Freiburg, Germany
[4] Astellas, Northbrook, IL USA
[5] Astellas Pharma GmbH, Munich, Germany
[6] Eberhard Karls Univ Tubingen, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [21] Pharmacoeconomic evaluation of using enzalutamide for treatment of patients with metastatic hormone-sensitive prostate cancer
    Avxentyev, N. A.
    Derkach, E., V
    Makarova, Yu, V
    ONKOUROLOGIYA, 2022, 18 (01): : 90 - 105
  • [22] Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
    Fiorentino, Francesca
    Di Rienzo, Paolo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 29 - 39
  • [23] Docetaxel Improves Survival in Metastatic Hormone-Sensitive Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 549 - 549
  • [24] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo, Adi
    Tannock, Ian F.
    Badillo, Francisco E. Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
  • [25] Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
    Armstrong, Andrew J.
    Azad, Arun A.
    Iguchi, Taro
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Alcaraz, Antonio
    Alekseev, Boris
    Shore, Neal D.
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Yamada, Shunsuke
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (15) : 1616 - +
  • [26] Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)
    Custodio-Cabello, Sara
    Pacheco-Barcia, Vilma
    Palka-Kotlowska, Magda
    Fernandez-Hernandez, Laura
    Del Alamo, Julio Fernandez
    Oliveros-Acebes, Eduardo
    Cabezon-Gutierrez, Luis
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (10) : 331e13 - 331e24
  • [27] Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
    Geynisman, Daniel M.
    Correa, Andres F.
    Ramamurthy, Chethan
    Beck, Robert J.
    Handorf, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [28] Treatment of metastatic hormone-sensitive prostate cancer
    Rane, Jayant K.
    Chowdhury, Amani
    Kinnaird, William
    Marks, Gillian
    Davda, Reena
    TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
  • [29] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting
    George, S.
    Gosain, R.
    Yendamuri, K.
    Boher, J. M.
    Mescam, G. Gravis
    Sweeney, C. J.
    Hutson, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1168 - S1169
12345